Stavrinides, V; Dalgleish, A; Copier, JP; Moore, CM
(2020)
Mycobacterial immunotherapy for prostate cancer: where can we go from here?
Nat Rev Urol, 17 (4).
pp. 189-190.
ISSN 1759-4820
https://doi.org/10.1038/s41585-020-0283-2
SGUL Authors: Dalgleish, Angus George
![[img]](https://openaccess.sgul.ac.uk/111628/1.hassmallThumbnailVersion/Nature%20reviews%20Oncology%20submission.pdf) ![](https://openaccess.sgul.ac.uk/111628/1.haspreviewThumbnailVersion/Nature%20reviews%20Oncology%20submission.pdf) Preview |
|
PDF
Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (114kB)
| Preview
|
Abstract
The effects of mycobacteria in prostate cancer have not been fully elucidated. Results of early studies indicated that mycobacterial immunotherapy conferred a survival benefit in patients with advanced prostate cancer, and recent evidence supports the safety and efficacy of new mycobacterial agents in many malignancies; thus, modern, carefully designed, randomized controlled trials of mycobacterial immunotherapy for prostate cancer could be warranted.
Statistics
Item downloaded times since 05 Feb 2020.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |